Date: 2012-06-18
Type of information: Production agreement
Compound: Plenachol™ (vitamin D3)
Company: D3 Pharma (UK) Encap Drug Delivery (UK)
Therapeutic area: Metabolic diseases
Type agreement: manufacturing
production
licensing
Action mechanism: Plenachol™ is a patented liquid-filled capsule formulation of vitamin D3 which was developed in conjunction with Encap and is available at three dose-strengths: 20,000, 40,000 and 100,000 international units. Plenachol™ has a unique formulation base which is free from animal derived excipients and peanut constituents. The utility of Encap’s world-class capsule liquid-filling technology secures Plenachol™ as a first and best-in-class high-dose oral vitamin D 3 product.
Disease: vitamin D deficiency and insufficiency
Details: The specialty pharmaceutical company D3 Pharma has announced its continuing partnership with the contract development and manufacturing organization (CDMO) Encap Drug Delivery to expedite the commercial manufacturing and product licensing programme for its proprietary high-dose oral vitamin D3 product, Plenachol™, for the treatment of vitamin D deficiency and insufficiency. Plenachol™ will continue to be made available as a Specials product during the pre-license phase via Encap Drug Delivery.
Financial terms:
Latest news:
